SCHEMBL17844289

SCHEMBL17844289

Cc1noc(C)c1-c1cnc2nc(C)n(Cc3ccc(CCCl)cc3)c2c1

nearest known ligand 0.56

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 18/20 0.56
EP300 Q09472 2/20 0.46
CREBBP Q92793 2/20 0.46
PDE10A Q9Y233 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20801548 0.93 BRD4 (0.48) BRD4EP300CREBBP
SCHEMBL17865270 0.91 BRD4 (0.58) BRD4EP300CREBBPPDE10A
SCHEMBL16347921 0.89 BRD4 (0.58) BRD4EP300CREBBPPDE10A
SCHEMBL17798129 0.88 BRD4 (0.72) BRD4EP300CREBBPPDE10A
SCHEMBL29920772 0.88 BRD4 (0.57) BRD4EP300CREBBPPDE10A
SCHEMBL17798166 0.88 BRD4 (0.57) BRD4EP300CREBBPPDE10A
SCHEMBL17860624 0.88 BRD4 (0.57) BRD4EP300CREBBPPDE10A
SCHEMBL17797964 0.88 BRD4 (0.58) BRD4EP300CREBBPPDE10A
SCHEMBL29920722 0.88 BRD4 (0.58) BRD4EP300CREBBPPDE10A
SCHEMBL17798093 0.87 BRD4 (0.55) BRD4EP300CREBBPPDE10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107406438-B Inhibitors of bromodomains 恒翼生物医药科技(上海)有限公司 2021-05-14 CN claimed
US-20170360760-A1 Inhibitors of Bromodomains ZENITH EPIGENETICS CORP. (CA) 2017-12-21 US claimed
CN-107406438-B Inhibitors of bromodomains 恒翼生物医药科技(上海)有限公司 2021-05-14 CN disclosed
US-10231953-B2 Inhibitors of bromodomains ZENITH EPIGENETICS LTD. (CA) 2019-03-19 US disclosed
US-10231953-B2 Inhibitors of bromodomains ZENITH EPIGENETICS LTD. (CA) 2019-03-19 US disclosed
US-20170360760-A1 Inhibitors of Bromodomains ZENITH EPIGENETICS CORP. (CA) 2017-12-21 US disclosed
US-20170360760-A1 Inhibitors of Bromodomains ZENITH EPIGENETICS CORP. (CA) 2017-12-21 US disclosed
US-20170360760-A1 Inhibitors of Bromodomains ZENITH EPIGENETICS CORP. (CA) 2017-12-21 US disclosed
EP-3233846-A1 INHIBITORS OF BROMODOMAINS Zenith Epigenetics Ltd. (CA) 2017-10-25 EP disclosed
WO-2016097863-A1 INHIBITORS OF BROMODOMAINS ZENITH EPIGENETICS CORP. (CA) 2016-06-23 WO disclosed
WO-2016097863-A1 INHIBITORS OF BROMODOMAINS ZENITH EPIGENETICS CORP. (CA) 2016-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170360760-A1 Inhibitors of Bromodomains BRDT, BRD3, BRPF3 BRD4 5/4885EP300 13/4885CREBBP 43/4885
US-10231953-B2 Inhibitors of bromodomains BRDT, BRD3, BRPF3 BRD4 5/4885EP300 13/4885CREBBP 43/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.